Hemab Therapeutics COAG

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Companies in Biotechnology nearest Hemab Therapeutics' size, closest first.

Company	Market cap	PE	Its 10y median PE	Fwd PE	P/S	Revenue growth	Net margin
COAGHemab Therapeutics	$1.6B	n/m	n/a		n/m	n/m	n/m
VCELVericel	$2.2B	92.5×	158×		7.1×	+23%	7.9%
ADMAAdma Biologics	$2.4B	15.3×	21.5×		4.7×	+8%	33.0%
MGTXMeiraGTx	$884.6M	13.0×	18.0×		2.2×	n/m	19.9%
KRYSKrystal Biotech	$9.2B	39.0×	42.7×		20.9×	+23%	54.8%
RGENRepligen	$10B	242×	120×		12.7×	+16%	5.3%
TECHBIO-TECHNE	$11.4B	63.1×	61.6×		9.4×	−0%	15.0%
PLXProtalix BioTherapeutics	$205.5M	11.1×	34.2×		2.5×	+30%	23.5%
HALOHalozyme Therapeutics	$14.3B	37.5×	21.3×		8.6×	+41%	24.9%
NBIXNeurocrine Biosciences	$14.5B	20.9×	42.8×		4.3×	+34%	20.9%
EXELExelixis	$16B	20.3×	22.8×		6.6×	+9%	35.3%
Peer median	$9.6B	29.2×	38.5×		6.8×	+23%	22.2%

Each number over time

• EPS
• Free cash flow
• Shares outstanding

Its groups

• Biotechnology
• Healthcare

Industry

Biotechnology

Sector

Healthcare